Author:
Thompson Aliza,Carroll Kevin,A. Inker Lesley,Floege Jürgen,Perkovic Vlado,Boyer-Suavet Sonia,W. Major Rupert,I. Schimpf Judith,Barratt Jonathan,Cattran Daniel C.,S. Gillespie Barbara,Kausz Annamaria,W. Mercer Alex,Reich Heather N.,H. Rovin Brad,West Melissa,Nachman Patrick H.
Abstract
IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve as reliable predictors of a treatment’s effect on long-term kidney outcomes in IgAN and be used as a basis for approval. Proteinuria was identified as the most widely recognized and well studied risk factor for progression to ESKD in IgAN. The workgroup performed a critical review of the data on proteinuria reduction as a surrogate end point for a treatment’s effect on progression to ESKD in IgAN. Epidemiologic data indicate a strong and consistent relationship between the level and duration of proteinuria and loss of kidney function. Trial-level analyses of data from 13 controlled trials also show an association between treatment effects on percent reduction of proteinuria and treatment effects on a composite of time to doubling of serum creatinine, ESKD, or death. We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment’s effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.
Publisher
American Society of Nephrology (ASN)
Subject
Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology
Reference54 articles.
1. Fostering Innovation, Advancing Patient Safety: The Kidney Health Initiative
2. Proteinuria as a surrogate end point—more data are needed
3. FDA-NIH Biomarker Working Group: BEST (Biomarkers, EndpointS, and other Tools) resource [Internet], Silver Spring, MD, Food and Drug Administration (US), 2016. Available at: http://www.ncbi.nlm.nih.gov/books/NBK326791/. Accessed February 24, 2018
4. Life expectancy for patients from the Southeastern United States with IgA nephropathy.;Hastings;Kidney Int Rep,2017
5. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). CDER biomarker qualification program [Internet]. Available at: https://www.fda.gov/drugs/developmentapprovalprocess/drugdevelopmenttoolsqualificationprogram/biomarkerqualificationprogram/default.htm
Cited by
155 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献